Although pioneers outsell late movers in many markets, in some cases i
nnovative late entry has produced some remarkably successful brands th
at outsell pioneers, The mechanisms through which innovative late move
rs outsell pioneers are unclear, To identify these mechanisms, the aut
hors develop a brand-level model in which brand sales are decomposed i
nto trials and repeat purchases. The model captures diffusion and mark
eting mix effects on brand trials and includes the differential impact
s of innovative and noninnovative competitors' diffusion on these effe
cts. The authors develop hypotheses on how the diffusion and marketing
mix parameters of the brands differ by market entry strategy (pioneer
ing, innovative late entry, and noninnovative late entry), The authors
test these hypotheses using data from 13 brands in two pharmaceutical
product categories. The results show that an innovative late mover ca
n create a sustainable advantage by enjoying a higher market potential
and a higher repeat purchase rate than either the pioneer or noninnov
ative late movers, growing faster than the pioneer, slowing the pionee
r's diffusion, and reducing the pioneer's marketing spending effective
ness. Innovative late movers are advantaged asymmetrically in that the
ir diffusion can hurt the sales of other brands, but their sales are n
ot affected by competitors' diffusion. In contrast, noninnovative late
movers face smaller potential markets, lower repeat rates, and less m
arketing effectiveness compared with the pioneer.